Clinical Trial Update: An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

An extension study of ANAVEX2-73 in mild to moderate Alzheimer's disease completed Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ANAVEX2-73 (blarcamesine)

Snippet

Sponsor: Anavex Life Sciences Corp. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED